Cosentyx (generic name: secukinumab) is a monoclonal antibody used to manage several inflammatory and autoimmune conditions. It targets and neutralizes interleukin-17A (IL-17A), a protein involved in the immune process that leads to inflammation and tissue damage. By binding to IL-17A, Cosentyx reduces inflammation, thereby preventing the progression of disease symptoms and supporting the health of the skin, joints, and spine.
This medication is indicated for use in adults and children aged 6 years and older with moderate to severe plaque psoriasis, in patients aged 2 years and older with psoriatic arthritis, and in adults with ankylosing spondylitis or non-radiographic axial spondyloarthritis. As of October 2023, Cosentyx is also approved for use in adults with moderate to severe hidradenitis suppurativa, a skin condition characterized by recurring painful nodules and abscesses.
By directly addressing IL-17A-driven inflammation, Cosentyx helps improve symptoms like skin redness, swelling, joint pain, and spinal stiffness.
Dosage
Use Cosentyx exactly as prescribed by your healthcare provider. Administration is via subcutaneous injection using prefilled syringes or pens, given by self-injection after training by a doctor or nurse.
For moderate to severe plaque psoriasis in adults and children aged 6 and older, and psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis in adults, the usual regimen starts with five weekly loading injections of 300 mg (two 150 mg injections) followed by a maintenance injection of 300 mg once monthly. In some cases, 150 mg may be used based on clinical response.
If a scheduled dose is missed, it should be administered as soon as possible, maintaining at least four-week intervals thereafter. Patients should follow medical guidance regarding injection technique and healthcare visit schedules to ensure ongoing treatment effectiveness and monitoring.
Storage
Cosentyx should be stored in the refrigerator at 2–8 °C (36–46 °F). Do not freeze. Keep the pens in the original carton to protect from light. If needed, the product may be kept at room temperature (not exceeding 30 °C / 86 °F) for up to 24 hours before administration.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.
Read the information leaflet that comes with the medication.
If a sudden allergic reaction (anaphylaxis) occurs shortly after taking Cosentyx, with symptoms like swelling of the face, tongue, or throat making it difficult to breathe or swallow, or there is wheezing, hives, rash, blistering, or peeling of the skin, call a doctor or 911 right away, or go to an emergency room immediately.
Most people who use Cosentyx do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include nasopharyngitis (sore throat), upper respiratory tract infection, diarrhea, headache, and oral herpes.
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Psoriatic arthritis (PsA) combines skin psoriasis with joint inflammation, leading to pain, stiffness, and potential long-term joint damage. Cosentyx alleviates joint swelling and maintains physical function.
Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) involve chronic spinal and pelvic inflammation, causing stiffness and reduced mobility. Cosentyx relieves spinal pain and enhances mobility.
Hidradenitis suppurativa (HS) is a chronic skin disease characterized by painful nodules and abscesses in areas such as armpits and groin. Cosentyx reduces inflammatory lesions and flare-ups starting as early as two weeks into treatment. Together, these conditions significantly affect daily life, and Cosentyx supports symptom relief and long-term control.